Site Sciences (SGHT) Q4 2025: Interventional Dry Eye Revenue Triples, Unlocking Reimbursed TAM
Site Sciences posted a pivotal Q4, with reimbursed interventional dry eye revenue up sharply and both business segments showing growth despite prior headwinds in glaucoma. The company’s disciplined operating expense management and strategic investments in market access signal a renewed growth trajectory for 2026. Management’s guidance and commentary point to expanding commercial infrastructure and market access as the levers for accelerating adoption and scaling both segments.
Summary
- Dry Eye Acceleration: Reimbursed interventional dry eye revenue growth validates market access strategy and expands addressable market.
- Glaucoma Stability: Interventional glaucoma segment returns to growth as market lapping and reimbursement stabilize.
- Growth Levers Set: Commercial investments and payer expansion position both segments for durable revenue growth in 2026 and beyond.
Performance Analysis
Site Sciences delivered broad-based growth in Q4, with total revenue rising 7% year over year and both interventional glaucoma and interventional dry eye segments contributing. The interventional glaucoma business, which represents the majority of revenue, grew 5% as the company navigated a more stable reimbursement and procedural environment after lapping 2025’s LCD changes. Ordering accounts increased 2% year over year, with healthy utilization and pricing gains from the OmniEdge product mix, partially offset by tariff costs.
The transformation story centered on interventional dry eye, where revenue more than doubled from the prior year, driven by the reimbursement milestone achieved in Q4. The company sold approximately 700 smart lids to 80 accounts, including 30 new accounts, as early adopters validated the reimbursed business model. Gross margin for dry eye improved to 68% from 51% as higher average selling prices and favorable mix took hold. Operating expenses dropped 25% year over year following a reduction in force, supporting a sharp narrowing of net loss and minimal cash burn for the quarter.
- Dry Eye Revenue Inflection: Early reimbursement traction in two major MAC regions unlocked new customer engagement and sequential growth.
- Glaucoma Execution: Stable market conditions and targeted investments in standalone procedures support renewed growth and pricing strength.
- Cost Structure Reset: Lower personnel and stock-based comp drove operating leverage, with Q4 marking the first full quarter of reduced expenses.
With $92 million in cash and no change in debt, Site Sciences enters 2026 positioned to scale commercial efforts in both segments while maintaining a path to cash flow breakeven without new equity raises.
Executive Commentary
"In 2026, we're building on this momentum with a clear strategy to return to double-digit growth while maintaining our operational rigor and financial discipline. Our flagship interventional technologies, Omni and TierCare, address two of the most prevalent anterior segment diseases, glaucoma and dry eye disease. With proven technologies, experienced teams, strong customer relationships, and a track record of execution, we believe we are well positioned to drive meaningful value as we continue building a leading interventional eye care company."
Paul Badawi, Co-founder and Chief Executive Officer
"We're entering 2026 from a position of strength. With the operating discipline and cost structure we need to support growth, And over time, we believe this positions us to achieve cash flow break even without the need to raise additional equity capital. The expected increase [in expenses] is driven primarily by targeted market access and commercial investments in both interventional dry eye and interventional glaucoma."
Jim Rodberg, Chief Financial Officer
Strategic Positioning
1. Interventional Dry Eye: Reimbursement as a Market Catalyst
Achieving fee schedules in two MAC regions (Novitas and First Coast) for TierCare, Site Sciences has validated its reimbursed procedure model. Early adoption by both new and existing glaucoma customers demonstrates the model’s synergy potential, with the addressable population in these MACs alone exceeding 700,000 patients. Management is prioritizing high-volume prescribers and expanding commercial infrastructure to accelerate penetration as additional payers are targeted in 2026.
2. Interventional Glaucoma: Standalone Market Activation
With LCD headwinds now lapped, the company’s Omni technology is positioned for renewed share gains in a stabilized, single-MIGS environment. Investments are being made in pseudophagic education and workflow integration, modeled after the cataract surgery consult process, to activate the underpenetrated standalone glaucoma market. This approach aims to shift treatment from medication to procedural intervention, expanding the TAM and supporting revenue durability.
3. Commercial Infrastructure and Market Access Investment
Site Sciences is deliberately expanding its commercial team and market access resources, especially in interventional dry eye. Management is balancing prudent expense growth (6–9% guided increase) with targeted investments to ensure readiness for further payer wins and to drive adoption in covered geographies. The company’s small but growing sales force is cited as the current constraint, not underlying market demand.
4. Synergistic Customer Base Across Segments
Many eye care providers manage both glaucoma and dry eye, creating opportunities for cross-selling and deeper account penetration. The overlap in patient populations and provider workflows enhances the scalability of the interventional eye care platform and supports a more durable, multi-segment growth model.
Key Considerations
This quarter marks a transition from reimbursement uncertainty to commercial execution, with Site Sciences leveraging its foundational wins to scale both business lines.
Key Considerations:
- Reimbursement Expansion Pace: The speed at which additional MACs and commercial payers establish fee schedules will be the primary gating factor for dry eye revenue acceleration.
- Commercial Team Scaling: Execution depends on expanding sales coverage and provider activation, particularly as current adoption remains a fraction of the covered dry eye population.
- Standalone Glaucoma Penetration: Success in shifting provider workflows and increasing standalone procedural volume will determine the segment’s long-term growth rate.
- Pricing Sustainability: Mix and ASP trends in both segments will affect margin trajectory, especially as new products (e.g., ULTRA) and reimbursement codes evolve.
Risks
Site Sciences’ growth is tightly linked to reimbursement expansion and successful commercial scaling. Delays in payer adoption, slow provider onboarding, or regulatory changes (such as future goniotomy code reductions) could pressure revenue and margins. Execution risk remains elevated as the company transitions from early adoption to broader market penetration, and competition in both interventional dry eye and glaucoma is intensifying.
Forward Outlook
For Q1 2026, Site Sciences guided to:
- Interventional glaucoma revenue up low single digits YoY, with Q1 expected to be the segment’s lowest quarter of the year
- Interventional dry eye revenue of approximately $1 million, with further ramp expected as reimbursement and commercial reach expand
For full-year 2026, management initiated guidance:
- Total revenue of $82 to $88 million (6–14% YoY growth)
- Interventional glaucoma $77 to $81 million (2–7% growth)
- Interventional dry eye $5 to $7 million (up sharply from $1.6 million in 2025)
- Adjusted operating expenses of $93 to $96 million (up 6–9%)
Management highlighted:
- Dry eye revenue guidance assumes no additional MAC wins, but ongoing market access efforts could create upside
- Glaucoma segment expected to accelerate in the second half as standalone activation and combo cataract efforts scale
Takeaways
Site Sciences enters 2026 at an inflection point, with reimbursement-driven dry eye growth and glaucoma stabilization setting the stage for multi-segment expansion. Investors should watch for further payer wins, commercial team buildout, and evidence of standalone glaucoma activation as key indicators of sustained growth.
- Dry Eye Reimbursement Validated: Early revenue ramp and customer engagement in newly covered regions confirm the business model and open a sizable TAM, but scaling depends on further payer adoption and sales force expansion.
- Glaucoma Market Reset: With LCD headwinds behind and procedural workflow investments underway, the segment is positioned for share gains and pricing leverage, particularly as standalone volume grows.
- Execution Watchpoint: The next 12 months will test management’s ability to convert early wins into durable, scalable growth across both business lines.
Conclusion
Site Sciences’ Q4 2025 performance signals a strategic pivot from reimbursement uncertainty to commercial execution, with both interventional dry eye and glaucoma segments positioned for renewed growth. The company’s disciplined cost structure and targeted investments in market access and commercial infrastructure create a foundation for sustainable expansion, but success will hinge on scaling adoption and payer coverage in 2026.
Industry Read-Through
The rapid revenue ramp in reimbursed interventional dry eye at Site Sciences highlights a broader industry shift toward procedural solutions with payer support in chronic eye disease. Competitors and adjacent device makers should note that market access wins can unlock outsized growth, but require significant commercial investment and provider education. The evolving reimbursement landscape in glaucoma, including future code changes, will shape strategic priorities for all players. Cross-segment synergies and provider workflow integration are emerging as critical differentiators in the ophthalmic device sector, suggesting that companies with multi-modal platforms and strong commercial execution will be best positioned for durable share gains.